Program
DA-5222
A development code. Also written as “DA-5222-R1”, “DA-5222-R2” and “DA-5222-R3”.
Its studies are led by Dong-A ST.
Furthest: phase 1, since May 19, 20253 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dong-A ST | 32 open or running | phase 1since May 19, 2025 | May 19, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2025First studies: 2 phase 1 studies in HealthyFirst studyNCT06993181, NCT06993168
- Jun 23, 2025Phase 1 study in HealthyNCT07046715 · 40 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07046715Healthy · South Korea | 1 | Completed | Aug 19, 2025 | 40 |
| NCT06993181Healthy · Korea, Republic of | 1 | Not yet recruiting | Jul 2025 | 48 |
| NCT06993168Healthy · Korea, Republic of | 1 | Not yet recruiting | Jul 2025 | 32 |
How it is read
Names in the registry
- “DA-5222”, 3 entries
- “DA-5222-R1”, 2 entries
- “DA-5222-R2”, 2 entries
- “DA-5222-R3”, 2 entries
Codes read as this program: DA5222.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.